There are currently 962 clinical trials in Ann Arbor, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Michigan, University of Michigan Comprehensive Cancer Center, University of Michigan Health System and C S Mott Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Recruiting
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Impact of Resident Participation in Post-ICU Follow Up Clinic
NCT05713669
Recruiting
This study is being conducted to describe the impact of a meeting between patients that were admitted to the intensive care unit (ICU) and a provider that cared for the patients during the period of critical illness. The study team is aiming to describe the effect this meeting has on the physician that previously cared for the patient. The study team hypothesizes that facilitating involvement in post-ICU clinic and creating longitudinal relationships between providers of critical care and survi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Professional Burnout
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718
Recruiting
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
04/02/2025
Locations: University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan
Conditions: ALK Fusion-positive Solid or CNS Tumors
Register for Updates
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595
Recruiting
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Advanced or Metastatic Colorectal Cancer
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/01/2025
Locations: Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan +1 locations
Conditions: Breast Cancer
Register for Updates
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT05164341
Recruiting
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Partial Lipodystrophy
Register for Updates
The M-Well Inpatient Whole Health Bundle
NCT06405347
Recruiting
This study will utilize a quasi-experimental pre-test/post-test design and will be conducted on the medical and medical/surgical units at the VA Ann Arbor Healthcare System. Hospitalized patients on the intervention units will be offered the Inpatient Whole Health Bundle. This study will evaluate overall satisfaction with the hospital environment and care as well as the bundle and components using a mailed survey of patients discharged from each unit. This study will also conduct a qualitative a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: VA Ann Arbor Healthcare System, Ann Arbor, Michigan
Conditions: Patient Satisfaction
Register for Updates
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT03842696
Recruiting
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
04/01/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Hematologic Diseases, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease, Acute Leukemia in Remission
Register for Updates
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
NCT06646289
Recruiting
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
Gender:
MALE
Ages:
5 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan Kellogg Eye Center, Ann Arbor, Michigan
Conditions: X-Linked Retinitis Pigmentosa
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan +1 locations
Conditions: Stage III Colon Cancer
Register for Updates
Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05537220
Recruiting
Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2025
Locations: University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan
Conditions: Retinitis Pigmentosa
Register for Updates
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Register for Updates